Evidence-Based Guide

Gout

A practical, evidence-based guide to gout symptoms, diagnosis, flare treatment, urate-lowering therapy, diet, and the warning signs that need urgent care.

Medically reviewed by Parth Bhavsar, MD
Last reviewed September 8, 2026
18 min read

What is the best treatment for gout in 2026?

Acute gout flares are treated promptly with an anti-inflammatory selected for the person's medical history: low-dose colchicine (1.2 mg, then 0.6 mg one hour later), an NSAID at an anti-inflammatory dose, or a short oral corticosteroid course. Long-term control requires urate-lowering therapy when indicated, usually allopurinol started low and titrated to serum urate below 6 mg/dL. The 2020 ACR guideline strongly recommends urate-lowering therapy for tophi, gout-related radiographic damage, or two or more flares yearly. Before allopurinol, people of Southeast Asian or African American ancestry should discuss HLA-B*58:01 testing because the allele is associated with severe skin reactions. A first hot, swollen joint or fever needs urgent in-person assessment to exclude infection.
Medically reviewed by Parth Bhavsar, MD. Updated September 8, 2026.
Editorial medical illustration representing gout and monosodium urate crystals in a joint
Gout occurs when monosodium urate crystals trigger intense inflammation in or around a joint.

Key Takeaways

  • Gout is an inflammatory arthritis caused by monosodium urate crystals; genetics play a large part, and diet changes usually lower urate only a little.[1][10]
  • For a flare, low-dose colchicine, an NSAID, or oral corticosteroids are first-line choices, selected for the person’s comorbidities and medicines.[1]
  • Allopurinol is the preferred first urate-lowering medicine, with a usual serum urate target below 6 mg/dL.[1]
  • Joint-fluid crystal analysis is the diagnostic reference standard, and the same fluid can be cultured when a hot, swollen joint could be infection.[14][27]
  • Meat, seafood, beer, spirits, and sugar-sweetened soda are associated with higher gout risk, while dairy and a DASH-style pattern are favorable.[9][15][16][18]
  • Fever with a hot, swollen joint needs urgent in-person assessment, because septic arthritis causes fever and joint swelling and delayed treatment can cause permanent joint damage.[27]

What Is Gout?

Gout is a crystal-deposition disease. It results from uric acid staying above the saturation point at which monosodium urate crystals form. It usually first shows up as severely painful attacks of joint inflammation, and over time joint damage, chronic pain, and tophi (urate deposits under the skin) can develop.[10] Gout affected about 3.9% of U.S. adults, or roughly 9.2 million people, in 2015 to 2016 NHANES data.[13]

The joint at the base of the big toe is the classic site, and the 2015 ACR/EULAR classification criteria also count attacks in the ankle or midfoot.[22] A high urate level alone is not enough to diagnose gout.[29]

Symptoms of a Gout Attack

A typical attack comes on quickly, with pain reaching its peak in less than 24 hours. The skin over the joint may be red, the joint may be too sore to touch, and walking or using the joint can be very hard. These are features the 2015 classification criteria count toward gout.[22] A hot, painful joint is not automatically gout. Septic arthritis also causes fever and a swollen, painful joint, usually just one.[27]

Important: A first-ever hot, swollen joint deserves an in-person assessment. Joint aspiration can identify crystals and rule out septic arthritis.

How Long Does a Gout Attack Last?

In the 2015 ACR/EULAR classification criteria, a typical episode reaches maximal pain in less than 24 hours and resolves within 14 days.[22] The 2012 ACR flare guideline recommended starting treatment within 24 hours of onset, based on expert consensus that early treatment leads to better patient-reported outcomes.[26] In the AGREE trial of early flares, 37.8% of people taking low-dose colchicine had at least 50% pain reduction at 24 hours without rescue medicine, compared with 15.5% on placebo.[2]

The timing matters in two practical ways. First, ACR guidance supports teaching people with gout to start treatment at the first signs of an attack, a "medication-in-pocket" approach, rather than waiting to see how bad it gets.[26][1] Second, a flare is not a reason to stop long-term urate-lowering therapy: the 2012 ACR guideline recommends continuing established urate-lowering therapy without interruption during an attack, and the febuxostat label says it need not be stopped if a flare occurs.[26][25] For a step-by-step guide to the first-line options, dosing, and home measures, see our gout attack treatment guide.

What Causes Gout: Hyperuricemia and Triggers

Genetic predisposition, diet, other illnesses, and medicines that raise uric acid all shape gout risk.[10] Diuretics, for example, were associated with a higher risk of gout in people with high blood pressure.[19] Diet matters, but diet changes usually move serum urate only a little.[1]

Common short-term triggers include a recent alcohol binge, a large purine-rich meal, illness, surgery, dehydration, and a sudden change in urate level after starting or stopping therapy. The goal is not to blame a single meal, but to reduce crystal burden and identify modifiable patterns.

Uric Acid Levels: What the Numbers Mean

Serum urate is reported in milligrams per deciliter (mg/dL). The 2020 ACR guideline defines asymptomatic hyperuricemia as a serum urate of 6.8 mg/dL or higher in someone who has never had a gout flare or tophus.[1] A U.S. national survey treated levels above 7.0 mg/dL as above the supersaturation point and defined hyperuricemia differently by sex, above 7.0 mg/dL in men and above 5.7 mg/dL in women; in 2015 to 2016, average serum urate was 6.0 mg/dL in men and 4.8 mg/dL in women.[13]

A high urate is a risk marker, but many people with one do not go on to develop gout: the ACR notes that among people with asymptomatic hyperuricemia above 9 mg/dL, only 20% developed gout within 5 years.[1] On urate-lowering therapy, the ACR target is below 6 mg/dL. The 2020 guideline deliberately sets no lower threshold for people with tophi, because no trial data support a specific lower number, although lower levels do speed the resolution of tophi.[1] For classification, the 2015 criteria advise using a urate value measured off urate-lowering therapy and more than 4 weeks after an episode began, and retesting under those conditions when practical.[22] For the full breakdown of ranges, thresholds, and treatment targets, see our uric acid levels guide.

What's Changed in 2024 to 2026

The core management approach remains treat-to-target urate lowering, low starting doses, and anti-inflammatory prophylaxis when beginning urate-lowering therapy.[1] Evidence has also clarified several decisions: the FAST trial found febuxostat noninferior to allopurinol for its cardiovascular endpoint, while CARES found higher cardiovascular and all-cause mortality in people with established cardiovascular disease, so individual cardiovascular history still matters.[3][4]

For uncontrolled gout treated with pegloticase, adding methotrexate raised the share of people with sustained urate lowering during month 6 from 38.5% to 71.0% in the MIRROR trial, and the gap persisted at month 12, 60.0% versus 30.8%.[7] In diabetes research, a large real-world cohort found lower 5-year gout incidence when SGLT2 inhibitors were added to metformin or insulin, with hazard ratios of 0.75 and 0.83.[11] A Japanese claims study, however, found that gout risk may be comparable between people starting metformin and people starting an SGLT2 inhibitor.[20] These are observational findings in people with diabetes.

United States gout prevalence trendBars show 3.9 percent in 2007 to 2008 and 3.9 percent in 2015 to 2016.U.S. adult gout prevalenceNHANES estimates, about 9.2 million adults in 2015 to 20163.9%3.9%2007-20082015-2016
U.S. adult gout prevalence, NHANES 2007 to 2008 and 2015 to 2016. [13]

How Gout Is Diagnosed

Finding monosodium urate crystals in fluid from a symptomatic joint or in a tophus is the reference standard, and the 2015 ACR/EULAR classification criteria treat it as sufficient on its own. When crystals are not available, the criteria score clinical, laboratory, and imaging features instead.[22] European diagnosis recommendations advise a search for crystals in everyone with suspected gout.[29] When infection is possible, joint fluid can be sent for cell count, Gram stain, and culture as well as crystal examination.[27]

Ultrasound may show a double-contour sign, and dual-energy CT can identify urate deposits. In a systematic review for the American College of Physicians, three studies of dual-energy CT showed sensitivities of 85% to 100% and specificities of 83% to 92%, and the double-contour sign had a pooled sensitivity of 74% and specificity of 88%, all with low strength of evidence. Results should be interpreted with the history and examination, not in isolation.[14]

Treating an Acute Gout Flare: Three First-Line Options

For a complete walkthrough of the first-line medicines, dosing, home measures, and when to seek urgent care, see our dedicated gout attack treatment guide, and read how colchicine differs from allopurinol in allopurinol vs colchicine.

Start treatment as soon as practical after symptoms begin. The 2020 ACR guideline strongly recommends colchicine, NSAIDs, or glucocorticoids as first-line choices and does not rank them, so selection is driven by patient factors such as other illnesses and past experience.[1] The 2012 ACR guideline lists cautions such as kidney or liver disease, heart failure, peptic ulcer disease, anticoagulation, diabetes, and infection risk.[26] The FDA-approved colchicine regimen for a flare is 1.2 mg at the first sign, then 0.6 mg one hour later.[12][1] In the AGREE trial, this low-dose approach (1.8 mg over one hour) gave early flare efficacy comparable to high-dose colchicine (4.8 mg over 6 hours), with a safety profile similar to placebo.[2]

Rest, ice, elevation, hydration, and avoiding alcohol can support medication treatment. Do not stop established allopurinol or febuxostat during a flare unless a clinician advises it.[26]

Medication Comparison Table

OptionTypical acute approachOften avoided or adjusted whenUseful fit
Low-dose colchicine1.2 mg, then 0.6 mg one hour laterKidney or liver impairment combined with P-gp or strong CYP3A4 inhibitor medicines; dose changes in kidney diseaseFlare that began within the past 36 hours
NSAIDFull anti-inflammatory dose, continued until the flare resolvesKidney disease, peptic ulcer disease, anticoagulation, heart failure, liver diseaseNo kidney, ulcer, bleeding, or heart failure concerns
Oral corticosteroidPrednisone or prednisolone, at least 0.5 mg/kg per day for 5 to 10 days, then stopDiabetes, ongoing infection or high infection risk, peptic ulcer diseaseNSAID or colchicine unsuitable

Colchicine has important interaction and dose-adjustment issues. The COLCRYS label says people with kidney or liver impairment should not be given colchicine together with P-gp or strong CYP3A4 inhibitors, and notes that fatal toxicity has been reported.[12] The 2012 ACR guideline names clarithromycin, erythromycin, cyclosporine, and disulfiram among major colchicine interactions, recommends full NSAID doses until the attack resolves, recommends oral colchicine only for attacks that began no more than 36 hours earlier, and gives the oral corticosteroid regimen in the table.[26]

Long-Term Urate-Lowering Therapy: Who Needs It and How to Titrate

Urate-lowering therapy is strongly recommended for people with one or more tophi, gout-related radiographic damage, or frequent flares, defined as two or more yearly. Allopurinol is preferred first-line, including for people with moderate-to-severe chronic kidney disease. Start low, at 100 mg a day or less and lower in chronic kidney disease, then titrate using serial serum urate measurements to a target below 6 mg/dL. Anti-inflammatory prophylaxis is strongly recommended when starting, continued for 3 to 6 months.[1]

Starting ULT during a flare can be considered when anti-inflammatory treatment is also provided. In a randomized trial, starting allopurinol during an acute attack, with indomethacin and colchicine given to everyone, caused no significant difference in daily pain, recurrent flares, or inflammatory markers.[24] When urate-lowering therapy is indicated, the ACR conditionally recommends starting it during the flare rather than waiting.[1]

Serum urate target and conceptual flare riskAn illustrative curve rises as serum urate rises from four to ten milligrams per deciliter. A line marks the target of six.Lower serum urate supports fewer flaresConceptual treat-to-target curve, not an individual prediction6.0410ACR targetSerum urate, mg/dLRelative flare risk
Conceptual illustration, not data. The 2020 ACR target is below 6 mg/dL for everyone on urate-lowering therapy, with no lower threshold set for tophi. [1]

Allopurinol vs Febuxostat vs Probenecid vs Pegloticase

AgentRoleKey considerations
AllopurinolPreferred first-line xanthine oxidase inhibitorStart low, titrate to target. Consider HLA-B*58:01 testing in higher-risk ancestry groups.
FebuxostatAlternative xanthine oxidase inhibitorReview cardiovascular history and the U.S. boxed warning.
ProbenecidUricosuric optionLess useful with reduced kidney function; requires adherence and hydration.
PegloticaseIV therapy for uncontrolled, refractory goutSpecialist infusion treatment; methotrexate co-therapy can improve sustained response.

The ACR strongly recommends switching to pegloticase when other urate-lowering approaches have failed to reach target and flares remain frequent or tophi persist, and considers an optimal trial of oral medicine appropriate first.[1] In pivotal trials, 42% of people receiving pegloticase every two weeks kept urate below 6 mg/dL in months three and six, compared with 0% on placebo.[6] The U.S. febuxostat label carries a boxed warning that gout patients with established cardiovascular disease had a higher rate of cardiovascular death than with allopurinol, and limits it to people for whom allopurinol has not worked well enough, is not tolerated, or is not advisable.[25] FAST later reported a different cardiovascular result in its population.[4] Uricosurics such as probenecid are not advised with kidney stones or moderate-to-severe chronic kidney disease, and people taking them should be counseled on hydration.[1]

HLA-B*58:01 Screening and Serious Skin Reactions

Allopurinol can cause severe skin reactions, including drug hypersensitivity syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which carry significant illness and death.[5] The HLA-B*58:01 allele is associated with a markedly elevated risk of allopurinol hypersensitivity. The ACR conditionally recommends testing before allopurinol for people of Southeast Asian descent, including Han Chinese, Korean, and Thai ancestry, and for African American patients.[1] In the original association study in Han Chinese patients, all 51 people with these severe reactions carried the allele, compared with 15% of allopurinol-tolerant controls.[5]

The allopurinol label says to stop it at the first appearance of a skin rash or other signs that may indicate an allergic reaction; some people with the most severe reactions also had fever, chills, and joint aches.[28] Seek immediate medical care for a new widespread or blistering rash.

Diet and Lifestyle: What the Evidence Actually Shows

For the full, food-by-food list of what to avoid and what to eat, see our gout diet: foods to avoid guide.

Diet supports medical treatment, but diet changes usually lower urate only a little, so they rarely replace treat-to-target ULT for people who meet guideline criteria.[1] Focus on repeatable changes, not punitive restriction. In a prospective study of men, the highest fifth of meat intake was associated with a relative risk of 1.41 for gout and the highest fifth of seafood intake with a relative risk of 1.51. The highest fifth of dairy intake was associated with a relative risk of 0.56, while purine-rich vegetables and total protein intake were not associated with higher risk.[15]

Food groupFinding in a 12-year prospective study of menPractical gout message
MeatHighest vs lowest fifth: relative risk 1.41Moderate portions, emphasize overall pattern
SeafoodHighest vs lowest fifth: relative risk 1.51Limit, particularly if a personal trigger
Purine-rich vegetablesNot associated with higher riskDo not eliminate solely for gout
Total proteinNot associated with higher riskFocus on the source, not the total
Dairy productsHighest vs lowest fifth: relative risk 0.56Dairy can fit well
Diet and gout risk in a prospective study of menHorizontal bars show relative risks of gout for the highest versus lowest fifth of intake: meat 1.41, seafood 1.51, dairy products 0.56. A line marks a relative risk of 1.Relative risk of gout, highest vs lowest fifth of intakePurine-rich vegetables and total protein were not associated with higher risk.MeatSeafoodDairy products1.411.510.56RR 1.0
Relative risks of incident gout from a 12-year prospective cohort of men. [15]

Cherries: In a case-crossover study of 633 people with gout, cherry intake over the prior two days was associated with 35% lower odds of a gout attack, odds ratio 0.65. This is promising observational evidence, not proof that cherries replace medication.[8] Fructose: Men drinking two or more sugar-sweetened sodas daily had a relative risk of 1.85 compared with less than one serving a month; diet soda was not associated with gout in that study.[9]

Alcohol: In one prospective cohort of men, beer was associated with a relative risk of 1.49 per daily 12-ounce serving and spirits with 1.15 per daily drink or shot, while wine was not significantly associated with gout (1.04 per daily 4-ounce serving).[16] Coffee and DASH: Drinking 4 to 5 cups of coffee a day was associated with a relative risk of 0.60, and 6 or more cups with 0.41.[17] The highest fifth of DASH diet scores was associated with a relative risk of 0.68 for incident gout.[18] These associations support a whole-diet approach, not a prescription to start coffee.

For someone who also needs blood-pressure treatment, medication choice belongs to a clinician. In a large observational study, losartan was associated with lower incident gout risk, relative risk 0.81, while diuretics were associated with higher risk, relative risk 2.36.[19]

Diet myth check: The 2012 ACR panel voted against oral complementary remedies such as cherry juice or extract, ginger, celery root, and charcoal as treatment for an acute attack.[26] Vitamin C supplements are not an answer either: in a randomized trial, 500 mg daily for 8 weeks lowered serum urate by a mean of only 0.014 mmol/L (0.23 mg/dL), compared with 0.118 mmol/L (1.9 mg/dL) when allopurinol was started or increased.[21] The 2020 ACR guideline no longer recommends vitamin C for gout.[1]

Gout and Cardiovascular or Metabolic Comorbidities

Chronic kidney disease and hypertension are strongly associated with gout.[13] These conditions affect medication selection. Cardiovascular decisions around febuxostat require particular care because the CARES and FAST trial populations and results differed.[3][4]

Colchicine is also being studied and used in selected cardiovascular settings. In COLCOT, low-dose colchicine reduced ischemic cardiovascular events after myocardial infarction, but that does not make it a substitute for standard gout or cardiac care.[23]

Gout vs Other Joint Conditions

For a side-by-side comparison focused specifically on calcium pyrophosphate disease, see our gout vs pseudogout guide.

Pseudogout, or calcium pyrophosphate deposition disease, can mimic gout but involves different crystals. Cellulitis affects the skin and soft tissue rather than the joint, while rheumatoid arthritis more often causes persistent, symmetric inflammatory joint symptoms. Septic arthritis causes fever and a swollen, painful joint, and delayed treatment can lead to permanent joint damage; joint fluid aspiration with crystal examination, Gram stain, and culture helps tell these conditions apart.[27]

Decision Framework: Home Care, Telehealth, or ER

Home measures can complement treatment for a familiar, mild flare while waiting for clinician guidance. A synchronous video visit can be appropriate for a recurrent flare in a patient with an established gout diagnosis and no warning signs, as well as for ULT initiation or titration, HLA-B*58:01 test ordering, diet counseling, follow-up urate monitoring, and medication interaction review. Any prescription by video still depends on the clinician's judgment and state licensure.

SituationAppropriate settingWhy
Known recurrent flare, no fever or new red flagsTelehealth can be appropriateHistory, visual exam, interaction review, and first-line prescriptions can often be handled by video.
ULT initiation, dose titration, HLA-B*58:01 order, diet counseling, urate follow-upTelehealth can be appropriateRequires history, lab coordination, and shared decision-making.
First-ever suspected gout or unclear diagnosisIn-personJoint aspiration may be needed to identify crystals and exclude infection.
Tophi needing debridement, ultrasound or dual-energy CT, refractory disease needing pegloticase infusionIn-person specialist careProcedures, imaging, and infusion monitoring require onsite services.
Fever, severe systemic symptoms, rapidly spreading redness, or inability to bear weightUrgent in-person or ER evaluationSeptic arthritis and other serious diagnoses must be excluded promptly.

Telehealth is a setting, not a diagnosis. A video visit should escalate to in-person care whenever the clinician cannot confidently distinguish a familiar flare from infection or another acute joint condition.

Red Flags: When Gout Needs Emergent Care

Seek same-day emergency or urgent evaluation for fever or chills with a hot joint, confusion or severe weakness, rapidly spreading redness, a wound near the joint, inability to bear weight, severe immune suppression, or a new blistering rash after allopurinol. These signs can indicate septic arthritis, serious infection, or a severe drug reaction rather than an uncomplicated flare. Septic arthritis causes fever and joint swelling, and delayed treatment can cause permanent joint damage.[27] The allopurinol label says to stop the drug at the first appearance of a skin rash.[28]

Frequently Asked Questions

A flare can settle even without treatment, but untreated urate crystal deposition can lead to recurrent flares, tophi, and joint damage. Treating the flare and, when indicated, lowering urate addresses different parts of the disease.[10]

No. The 2012 ACR gout guideline recommends continuing established urate-lowering therapy without interruption during an attack, and the febuxostat label says it need not be stopped if a flare occurs. Treat the flare separately with an appropriate anti-inflammatory medicine, and check with your clinician if unsure.[26][25]

Not on its own. In the 2015 classification criteria, a urate level of 4 to under 6 mg/dL counts neither for nor against gout, while a level under 4 mg/dL counts against it, and the criteria advise testing more than 4 weeks after an episode began when possible.[22] When the diagnosis is uncertain, finding monosodium urate crystals in joint fluid is the reference test.[14]

Low-dose colchicine, an NSAID, and oral corticosteroids are all first-line options with similar efficacy, so the best first choice depends on the person's other illnesses, medicines, and past experience.[1]

The ACR strongly recommends urate-lowering therapy for people with tophi, gout-related radiographic damage, or frequent flares, defined as two or more per year.[1]

No. Cherry intake was associated with fewer recurrent flares in an observational study, but it does not replace treat-to-target urate lowering when that therapy is indicated.[8]

No. Purine-rich vegetables were not associated with incident gout in a large prospective study. Overall dietary pattern matters more than eliminating vegetables.[15]

Yes. Beer and spirits were associated with higher gout risk in prospective data.[16] The 2020 ACR guideline conditionally recommends limiting alcohol for everyone with gout.[1]

For people receiving urate-lowering therapy, the 2020 ACR target is below 6 mg/dL. The guideline sets no lower threshold for people with tophi, because no trial data support a specific lower number.[1]

Allopurinol is preferred first-line. The U.S. febuxostat label limits it to people for whom allopurinol has not worked well enough, is not tolerated, or is not advisable, and carries a boxed warning about cardiovascular death in people with established cardiovascular disease.[25] CARES and FAST produced different cardiovascular findings, so cardiovascular history should be reviewed.[3][4]

For a patient with recurrent, previously diagnosed gout and no warning signs, a synchronous video visit can be appropriate for flare treatment, medication review, or urate monitoring. A first hot swollen joint or systemic illness needs in-person evaluation, because joint fluid aspiration may be needed to check for infection.[27]

Seek emergency evaluation for fever or chills with a hot swollen joint, rapidly spreading redness, inability to bear weight, severe illness, immune suppression, or concern for septic arthritis. Delayed treatment of septic arthritis can cause permanent joint damage.[27]

References

  1. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research. 2020;72(6):744-760. doi:10.1002/acr.24180. PMID: 32391934. https://pmc.ncbi.nlm.nih.gov/articles/PMC10563586/
  2. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis & Rheumatism. 2010;62(4):1060-1068. doi:10.1002/art.27327. PMID: 20131255. https://pubmed.ncbi.nlm.nih.gov/20131255/
  3. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine. 2018;378(13):1200-1210. doi:10.1056/NEJMoa1710895. PMID: 29527974. https://pubmed.ncbi.nlm.nih.gov/29527974/
  4. Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. The Lancet. 2020;396(10264):1745-1757. doi:10.1016/S0140-6736(20)32234-0. PMID: 33181081. https://pubmed.ncbi.nlm.nih.gov/33181081/
  5. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proceedings of the National Academy of Sciences USA. 2005;102(11):4134-4139. doi:10.1073/pnas.0409500102. PMID: 15743917. https://pubmed.ncbi.nlm.nih.gov/15743917/
  6. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711-720. doi:10.1001/jama.2011.1169. PMID: 21846852. https://pubmed.ncbi.nlm.nih.gov/21846852/
  7. Botson JK, Saag K, Peterson J, et al. A Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12-Month Findings. ACR Open Rheumatology. 2023;5(8):407-418. doi:10.1002/acr2.11578. PMID: 37385296. https://pubmed.ncbi.nlm.nih.gov/37385296/
  8. Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi HK. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis & Rheumatism. 2012;64(12):4004-4011. doi:10.1002/art.34677. PMID: 23023818. https://pmc.ncbi.nlm.nih.gov/articles/PMC3510330/
  9. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309-312. doi:10.1136/bmj.39449.819271.BE. PMID: 18244959. https://pubmed.ncbi.nlm.nih.gov/18244959/
  10. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nature Reviews Rheumatology. 2015;11(11):649-662. doi:10.1038/nrrheum.2015.91. PMID: 26150127. https://pubmed.ncbi.nlm.nih.gov/26150127/
  11. Preston FG, Anson M, Riley DR, Ibarburu GH, Henney A, Lip GYH, et al. SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum. Clinical Therapeutics. 2024;46(11):835-840. doi:10.1016/j.clinthera.2024.06.021. PMID: 39068059. https://pubmed.ncbi.nlm.nih.gov/39068059/
  12. AR Scientific Inc. COLCRYS (colchicine) tablet, film coated: prescribing information. DailyMed, U.S. National Library of Medicine. Revised March 2012. Accessed November 7, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ecaa34e-1bed-49a5-b97c-a8f8c0d885a7
  13. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis & Rheumatology. 2019;71(6):991-999. doi:10.1002/art.40807. PMID: 30618180. https://pubmed.ncbi.nlm.nih.gov/30618180/
  14. Newberry SJ, FitzGerald JD, Motala A, et al. Diagnosis of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine. 2017;166(1):27-36. doi:10.7326/M16-0462. PMID: 27802505. https://pubmed.ncbi.nlm.nih.gov/27802505/
  15. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. New England Journal of Medicine. 2004;350(11):1093-1103. doi:10.1056/NEJMoa035700. PMID: 15014182. https://pubmed.ncbi.nlm.nih.gov/15014182/
  16. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. The Lancet. 2004;363(9417):1277-1281. doi:10.1016/S0140-6736(04)16000-5. PMID: 15094272. https://pubmed.ncbi.nlm.nih.gov/15094272/
  17. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis & Rheumatism. 2007;56(6):2049-2055. doi:10.1002/art.22712. PMID: 17530645. https://pubmed.ncbi.nlm.nih.gov/17530645/
  18. Rai SK, Fung TT, Lu N, Keller SF, Curhan GC, Choi HK. The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study. BMJ. 2017;357:j1794. doi:10.1136/bmj.j1794. PMID: 28487277. https://pubmed.ncbi.nlm.nih.gov/28487277/
  19. Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. doi:10.1136/bmj.d8190. PMID: 22240117. https://pubmed.ncbi.nlm.nih.gov/22240117/
  20. Hatano M, Okada A, Sasabuchi Y, et al. Gout incidence in metformin versus sodium-glucose co-transporter-2 inhibitor users: a retrospective cohort study. Rheumatology (Oxford). 2025;64(7):4164-4171. doi:10.1093/rheumatology/keaf136. PMID: 40127201. https://pubmed.ncbi.nlm.nih.gov/40127201/
  21. Stamp LK, O'Donnell JL, Frampton C, Drake JM, Zhang M, Chapman PT. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. Arthritis & Rheumatism. 2013;65(6):1636-1642. doi:10.1002/art.37925. PMID: 23681955. https://pubmed.ncbi.nlm.nih.gov/23681955/
  22. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & Rheumatology. 2015;67(10):2557-2568. doi:10.1002/art.39254. PMID: 26352873. https://pubmed.ncbi.nlm.nih.gov/26352873/
  23. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine. 2019;381(26):2497-2505. doi:10.1056/NEJMoa1912388. PMID: 31733140. https://pubmed.ncbi.nlm.nih.gov/31733140/
  24. Taylor TH, Mecchella JN, Larson RJ, Kerin KD, Mackenzie TA. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. The American Journal of Medicine. 2012;125(11):1126-1134.e7. doi:10.1016/j.amjmed.2012.05.025. PMID: 23098865. https://pubmed.ncbi.nlm.nih.gov/23098865/
  25. Takeda Pharmaceuticals America, Inc. ULORIC (febuxostat) tablet: prescribing information, including boxed warning for cardiovascular death. DailyMed, U.S. National Library of Medicine. Revised April 2023. Accessed November 7, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54de10ef-fe5f-4930-b91d-6bbb04c664bd
  26. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care & Research. 2012;64(10):1447-1461. doi:10.1002/acr.21773. PMID: 23024029. https://pubmed.ncbi.nlm.nih.gov/23024029/
  27. MedlinePlus Medical Encyclopedia, U.S. National Library of Medicine. Septic arthritis. Review date May 12, 2025. Accessed November 7, 2026. https://medlineplus.gov/ency/article/000430.htm
  28. Prometheus Laboratories Inc. ZYLOPRIM (allopurinol) tablet: prescribing information. DailyMed, U.S. National Library of Medicine. Updated November 30, 2009. Accessed November 7, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=342832b5-1a32-4bea-bc49-ab0fd152154e
  29. Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Annals of the Rheumatic Diseases. 2020;79(1):31-38. doi:10.1136/annrheumdis-2019-215315. PMID: 31167758. https://pubmed.ncbi.nlm.nih.gov/31167758/

About the Author

Parth Bhavsar, MD is a board-certified family medicine physician and founder of TeleDirectMD. His editorial work focuses on practical, evidence-based guidance for common acute and chronic conditions.

All content on this page reflects the cited evidence and was last reviewed September 8, 2026.